Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Dementia

Reduction in antipsychotic use by dementia patients must continue, says Cameron

The government wants to see a “significant” reduction in inappropriate prescribing of antipsychotic drugs to people with dementia in England in the next five years.

Antipsychotic drugs should not be the first resort for treating people with dementia, it says. And health and social care workers should consider what else might be triggering challenging behaviour in patients, such as an untreated urinary tract infection, which can cause delirium, or untreated pain.

The government’s call is outlined in the ‘Prime Minister’s Challenge on Dementia 2020’ report published on 21 February 2015.

Statistics from the NHS Health and Social Care Information Centre’s 2012 audit on dementia and antipsychotic prescribing, which David Cameron’s report highlights, found that the number of antipsychotic prescriptions for patients with dementia fell by 52% between 2008 and 2011. Although the audit identified a decrease, it did not address the issue of whether the drugs were being prescribed appropriately. It also only collected data from patients registered with GP practices.

The government now wants to see an international dementia institute established in England and more money invested in drug and diagnostic development and research.

There should be more partnerships created between academia, patient charities, the NHS and the private sector to make England a world-class leader in the discovery of dementia treatments, according to the report.

The government is also keen to see the creation of a global framework for dementia research to speed up the development of disease modifying therapies that are currently planned to be launched by 2025.

The 2020 challenge comes within a week of the launch of a £30m national network of research centres by the charity Alzheimer’s Research UK. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067943

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.